Join
Live feed
·
PRReleasevia Quantisnow
iBio Inc. logo

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

ByQuantisnow·Wall Street's wire, on your screen.
IBIO· iBio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IBIO (iBio Inc.) and more on Quantisnow.